argenx to Present at Upcoming Investor Conferences

Core Insights - argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [2] - The company is participating in several investor conferences in March 2024, including the TD Cowen 44th Annual Health Care Conference, the Leerink Global Biopharma Conference, and the Barclays Global Healthcare Conference [1] Company Overview - argenx partners with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [2] - The company has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in multiple regions including the U.S., Japan, Israel, the EU, the UK, Canada, and China [2] - argenx is evaluating its drug efgartigimod in various serious autoimmune diseases and advancing several earlier-stage experimental medicines within its therapeutic franchises [2]